Treatments in immunology and rare genetic diseases have grabbed the limelight.

The 2019 class of top drug launches shows the booming of expensive orphan drugs that are based on novel technologies as well as the undying enthusiasm about the growing immunology market.

At the top of the list is Alexion’s Soliris follow-up, Ultomiris. The manufacturer has priced Ultomiris at a 10% discount to Soliris and is aiming to convert 70% of Soliris patients to the improved therapy.

Two gene therapies are included: Novartis’ spinal muscular atrophy treatment Zolgensma and Bluebird Bio’s Zynteglo for beta-thalassemia. 

The assessment is based on @EvaluatePharma projections.